Proposed Collection of A specification The proposed dose is Analysis of proposed Failure to capture the Use Transparent to – Dose Proposed of a dose that is assessed by the dose by proposed dose is likely some users of system Doses being requested Authoriser and indication/condition to result in approval (see security matrix). for treatment. provided compliant is important as part of and supply of the No disclosure other with the dose range for performance review maximum dose than at level of each indication in the and by linking to the allowable in the Criteria aggregated Criteria for use, will be clinical outcome, will for Use in instance, reports for clinical approved. Given that a provide evidence of resulting in potential governance and Ig range is permissible, minimal effective over prescription and governance purposes. the clinical dose in the future. not achieving cost circumstance will effective treatment. (NBA) determine the individual patient need. (Authoriser, NBA) Dispensing Distribution The that Capturing and Failure to capture and Use Transparent to – Site Site will be providing transparency display the dispensing some users of system (BloodNet) responsible for of the dispensing site is site is likely to result in (see security matrix). dispensing important to ensure errors in the availability No disclosure other immunoglobulin that treatment is of product and delays than at level of product to the provided at the correct to access and aggregated patient. location for the patient. treatment delivery. reports for clinical In some instances, the governance and Ig Treating Specialist governance purposes. (overall responsible for care) may be in a capital city; however,
Proposed Dose Collection of Proposed Doses A specification of a dose that is being requested for treatment. The proposed dose is assessed by the Authoriser and provided compliant with the dose range for each indication in the Criteria for use, will be approved. Given that a range is permissible, the clinical circumstance will determine the individual patient need. (Authoriser, NBA) Analysis of proposed dose by indication/condition is important as part of performance review and by linking to the clinical outcome, will provide evidence of minimal effective dose in the future. (NBA) Failure to capture the proposed dose is likely to result in approval and supply of the maximum dose allowable in the Criteria for Use in instance, resulting in potential over prescription and not achieving cost effective treatment. Use – Transparent to some users of system (see security matrix). No disclosure other than at level of aggregated reports for clinical governance and Ig governance purposes. Dispensing Site Distribution Site (BloodNet) The that will be responsible for dispensing immunoglobulin product to the patient. Capturing and providing transparency of the dispensing site is important to ensure that treatment is provided at the correct location for the patient. In some instances, the Treating Specialist (overall responsible for care) may be in a capital city; however, Failure to capture and display the dispensing site is likely to result in errors in the availability of product and delays to access and treatment delivery. Use – Transparent to some users of system (see security matrix). No disclosure other than at level of aggregated reports for clinical governance and Ig governance purposes.